drugset / Trial / NCT03603795
Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
Phase 2
Active not recruiting
110 enrolled
French Innovative Leukemia Organisation
Novartis Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction chemotherapy. A phase II multicenter and randomized placebo-controlled study
Timeline
- Start
- 2018-10-11
- Primary completion
- 2022-06-15
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 100 mg | Oral |
| Subject | Eltrombopag | Small molecule | 200 mg | Oral |